Brokerages Anticipate Clovis Oncology (NASDAQ:CLVS) to Announce -$0.43 EPS

Brokerages predict that Clovis Oncology (NASDAQ:CLVSGet Rating) will announce earnings of ($0.43) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Clovis Oncology’s earnings. The lowest EPS estimate is ($0.56) and the highest is ($0.31). Clovis Oncology reported earnings of ($0.64) per share during the same quarter last year, which would indicate a positive year over year growth rate of 32.8%. The business is expected to announce its next earnings results on Monday, January 1st.

On average, analysts expect that Clovis Oncology will report full-year earnings of ($1.59) per share for the current year, with EPS estimates ranging from ($2.08) to ($1.16). For the next fiscal year, analysts anticipate that the business will report earnings of ($0.90) per share, with EPS estimates ranging from ($1.10) to ($0.72). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Clovis Oncology.

Clovis Oncology (NASDAQ:CLVSGet Rating) last announced its quarterly earnings data on Wednesday, February 23rd. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.60) by $0.11. The firm had revenue of $35.97 million during the quarter, compared to the consensus estimate of $39.30 million. During the same quarter in the prior year, the firm posted ($0.74) earnings per share.

A number of brokerages recently issued reports on CLVS. HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Clovis Oncology in a research note on Thursday, February 24th. StockNews.com began coverage on Clovis Oncology in a research report on Thursday, March 31st. They set a “hold” rating on the stock.

Shares of Clovis Oncology stock opened at $2.28 on Wednesday. Clovis Oncology has a 52-week low of $1.35 and a 52-week high of $7.24. The stock’s 50-day simple moving average is $1.90 and its 200 day simple moving average is $2.83.

Several institutional investors and hedge funds have recently made changes to their positions in CLVS. Invesco Ltd. increased its position in shares of Clovis Oncology by 92.5% during the second quarter. Invesco Ltd. now owns 40,072 shares of the biopharmaceutical company’s stock valued at $232,000 after buying an additional 19,254 shares during the period. Parametric Portfolio Associates LLC increased its position in shares of Clovis Oncology by 19.2% in the second quarter. Parametric Portfolio Associates LLC now owns 90,836 shares of the biopharmaceutical company’s stock worth $527,000 after purchasing an additional 14,658 shares during the last quarter. Newbridge Financial Services Group Inc. increased its position in shares of Clovis Oncology by 111.0% in the third quarter. Newbridge Financial Services Group Inc. now owns 6,653 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 3,500 shares during the last quarter. SG Americas Securities LLC increased its position in shares of Clovis Oncology by 274.0% in the third quarter. SG Americas Securities LLC now owns 71,350 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 52,271 shares during the last quarter. Finally, Cambridge Investment Research Advisors Inc. increased its position in shares of Clovis Oncology by 5.0% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 66,975 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 3,185 shares during the last quarter. Hedge funds and other institutional investors own 48.81% of the company’s stock.

About Clovis Oncology (Get Rating)

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

See Also

Get a free copy of the Zacks research report on Clovis Oncology (CLVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.